JPRN-UMIN000022179已完成未知
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patients - The effect of denosumab on hemodialysis patients with osteoporosis
Yujinkai Medical Corporation Yujin-yamazaki Hospital0 个研究点目标入组 38 人开始时间: 2016年5月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patient who have the contraindication for denosumab
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis. FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months)Treatment of postmenopausal osteoporosisMedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2004-000138-35-GBAmgen Inc7,869
招募中
2 期
A phase II clinical trial of denosumab treatment for advanced non-small cell lung cancer with bone metastasisnon-small cell lung cancerJPRN-UMIN000008314Dokkyo Medical University Department of Pulmonary Medicine and Clinivcal Immunology40
已完成
不适用
Efficacy and safety of denosumab for the treatment of osteoporosis in patients with renal failureOsteoporosisJPRN-UMIN000011992ephrology Center, Toranomon Hospital Nephrology Center, Toranomon Hospital Kajigaya40
已完成
2 期
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingBreast CancerJPRN-UMIN000013863Department of Endocrine and breast cancer, Kyoto Prefectural University of medicine100
已完成
2 期
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingbreast cancerJPRN-UMIN000027425Kyoto Prefectural Universuty of Medicine100